Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Lumakras symbols : Amgn save search
AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB)
Published: 2023-12-26 (Crawled : 14:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.36%
H: 1.17%
C: -0.59%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.01%
H: 0.21%
C: -0.08%
lumakras update
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Published: 2023-10-22 (Crawled : 16:20) - prnewswire.com
CCXI | $51.99 -0.04%
|
Health Technology
| Email alert
Add to watchlist
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
| Email alert
Add to watchlist
BEIGF | $14.29 -9.87% 2.1K
|
n/a
| Email alert
Add to watchlist
lumakras cancer plus
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC
Published: 2023-09-10 (Crawled : 16:20) - prnewswire.com
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
| Email alert
Add to watchlist
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
| Email alert
Add to watchlist
BEIGF | $14.29 -9.87% 2.1K
|
n/a
| Email alert
Add to watchlist
CCXI | $51.99 -0.04%
|
Health Technology
| Email alert
Add to watchlist
lumakras plus
AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING
Published: 2023-08-21 (Crawled : 20:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.27%
H: 0.99%
C: -0.67%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.18%
H: 0.06%
C: -1.01%
lumakras fda treatment meeting application
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023
Published: 2023-06-04 (Crawled : 12:20) - prnewswire.com
BEIGF | $14.29 -9.87% 2.1K
|
n/a
| Email alert
Add to watchlist
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
| Email alert
Add to watchlist
CCXI | $51.99 -0.04%
|
Health Technology
| Email alert
Add to watchlist
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
lumakras asco
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
Published: 2022-10-11 (Crawled : 12:00) - globenewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.12%
H: 2.63%
C: 1.59%
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 1.06%
H: 3.53%
C: 0.95%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 3.16%
H: 4.59%
C: 2.48%
bbp-398 lumakras fda designation lung pharma trial cancer fast track designation
LUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Published: 2022-09-12 (Crawled : 09:00) - prnewswire.com
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.16%
C: 0.06%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.88%
H: 3.78%
C: 3.73%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
lumakras response cancer
LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER
Published: 2022-09-11 (Crawled : 00:00) - prnewswire.com
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.16%
C: 0.06%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.88%
H: 3.78%
C: 3.73%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
lumakras lung trial positive cancer
AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
Published: 2022-08-30 (Crawled : 21:00) - prnewswire.com
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: 0.12%
H: 0.16%
C: -0.31%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 3.3%
H: 1.98%
C: 0.39%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 1.03%
H: 0.95%
C: -0.53%
lumakras lung topline trial cancer
LUMAKRAS® (SOTORASIB) CODEBREAK 100 STUDY SHOWS TWO-YEAR OVERALL SURVIVAL OF 32.5% IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
Published: 2022-04-10 (Crawled : 16:20) - prnewswire.com
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
| Email alert
Add to watchlist
lumakras 100 cancer
Global Lumakras Drug Market By Therapy Type, Disease Indication, and Region (Including COVID-19 Impact Analysis): A Report by Absolute Markets Insights
Published: 2022-03-14 (Crawled : 16:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.01%
H: 0.71%
C: 0.0%
RVMD S | $34.95 -2.46% -2.52% 1.2M
|
Health Technology
|
| O: 0.15%
H: 0.72%
C: -9.31%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 1.45%
H: 18.94%
C: 7.04%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.78%
H: 3.11%
C: -5.4%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 1.34%
H: 0.0%
C: 0.0%
covid-19 lumakras drug covid disease report therapy
AMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022
Published: 2022-03-08 (Crawled : 22:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.09%
H: 5.56%
C: 4.68%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.81%
H: 0.13%
C: -1.18%
lumakras
LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL
Published: 2022-02-14 (Crawled : 23:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 4.23%
H: 6.03%
C: 2.76%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.33%
H: 0.52%
C: -0.47%
lumakras trial 100 cancer pancreatic
LUMAKRAS® (sotorasib) Receives Approval In Japan For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Published: 2022-01-20 (Crawled : 11:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 3.95%
H: 2.8%
C: 1.37%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.07%
lumakras approval cel lung cancer cancer
BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation
Published: 2022-01-13 (Crawled : 12:30) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -5.11%
H: 1.25%
C: -4.2%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
bbp-398 lumakras solid tumors potential collaboration